The company's stable returns and lack of reinvestment suggest it won't be a multi-bagger. The declining stock price indicates investor pessimism about this trend improving.
Hain Celestial's Q2 results were disappointing, missing key targets like revenue and EPS. Despite progress on its Hain Reimagined strategy, its size could be a disadvantage against larger competitors. The company's revenue has been declining, and Wall Street expects only a 4.9% growth in sales over the next year.
CEO Wendy Davidson believes Jefferson's extensive experience will enhance performance culture and benefit Hain Celestial Group's future growth. Jefferson also looks forward to enhancing employee involvement and boosting Hain's status as a purpose-led organization.
Despite recent stock upticks, last year's performance hinted at ongoing issues, underperforming a half-decade annualized loss of 9%. Persistent low share price could signal the need for prudent recovery strategies.
Hain Celestial's strategic turnaround plan emphasizes diversification and operational streamlining. Its focus on snack, baby, and children's food, and beverages brands signals potential market growth.
With stagnant ROCE and capital employed, and a major fall in stock value, Hain Celestial Group is unlikely to deliver multi-bagger returns soon. Investors are suggested to look for alternatives with higher returns and robust balance sheets.
Gapping up In reaction to earnings/guidance: •$索爾工業(THO.US)$+2.5% Other news: •$Acumen Pharmaceuticals(ABOS.US)$+76.8% (in response with BIIB) •$渤健公司(BIIB.US)$+45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint) •$Nano X Imaging(NNOX.US)$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system) •$Ocugen(OCGN.US)$+9.3% (en...
Now that we’re into the third quarter, we’re stating to see the pundits sound off on what the Q2 economic data will show – and some of them are openly saying that second quarter GDP will record a contraction. Coming on the heels of the 1.6% contraction in Q1, this will put the US in a technical recession. Along with rising inflation and the Fed’s turn to higher rates and monetary tightening, this adds up a darkening ec...
海恩時富股票討論區
In reaction to earnings/guidance:
• $索爾工業(THO.US)$ +2.5%
Other news:
• $Acumen Pharmaceuticals(ABOS.US)$+76.8% (in response with BIIB)
• $渤健公司(BIIB.US)$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging(NNOX.US)$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen(OCGN.US)$ +9.3% (en...
$Frontier Communications(FYBR.US)$ 6% HIGHER; will replace The Hain Celestial Group Inc. (HAIN) in the S&P Midcap 400
$海恩時富(HAIN.US)$ 4% HIGHER; $Frontier Communications(FYBR.US)$ will replace The $海恩時富(HAIN.US)$ in the S&P Midcap 400 ...
In reaction to earnings/guidance:
• $GoodRx(GDRX.US)$ +38.5%, $EDGIO(EGIO.US)$ +13.5%, $Lemonade(LMND.US)$ +10.7%, $Desktop Metal(DM.US)$ +8.5%, $ShockWave Medical(SWAV.US)$ +8.2%, $Pubmatic(PUBM.US)$ +8.1%, $Olaplex(OLPX.US)$ +7%, $Vivid Seats(SEAT.US)$ +6.4%, $Noble(NE.US)$ +6.3%, $艾斯本科技(AZPN.US)$ +5.4%, $艾倫建材(AAON.US)$ +5%, $Hudbay Minerals(HBM.US)$ +5%, $Vivint Smart Home(VVNT.US)$ +4.9%, $Vivint Smart Home(VVNT.US)$ +4...
暫無評論